Massachusetts Financial Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.3M | Buy |
102,414
+461
| +0.5% | +$68.4K | 0.01% | 693 |
|
|
2026
Q1 | $13.4M | Sell |
101,953
-24,388
| -19% | -$3.24M | ﹤0.01% | 698 |
|
|
2025
Q4 | $17.9M | Sell |
126,341
-10,415
| -8% | -$1.51M | 0.01% | 662 |
|
|
2025
Q3 | $19.2M | Sell |
136,756
-43,503
| -24% | -$5.89M | 0.01% | 633 |
|
|
2025
Q2 | $22.7M | Buy |
180,259
+29,598
| +20% | +$3.39M | 0.01% | 596 |
|
|
2025
Q1 | $16.7M | Buy |
150,661
+330
| +0.2% | +$41.8K | 0.01% | 614 |
|
|
2024
Q4 | $20.5M | Sell |
150,331
-12,723
| -8% | -$1.57M | 0.01% | 597 |
|
|
2024
Q3 | $18.8M | Buy |
163,054
+7,069
| +5% | +$969K | 0.01% | 599 |
|
|
2024
Q2 | $21.5M | Buy |
155,985
+4,112
| +3% | +$564K | 0.01% | 574 |
|
|
2024
Q1 | $20.9M | Sell |
151,873
-23,904
| -14% | -$3.26M | 0.01% | 574 |
|
|
2023
Q4 | $23.2M | Sell |
175,777
-133
| -0.1% | -$15.3K | 0.01% | 556 |
|
|
2023
Q3 | $19.8M | Sell |
175,910
-49
| -0% | -$5.16K | 0.01% | 561 |
|
|
2023
Q2 | $16.6M | Buy |
175,959
+7,695
| +5% | +$752K | 0.01% | 575 |
|
|
2023
Q1 | $17M | Sell |
168,264
-12,751
| -7% | -$1.33M | 0.01% | 572 |
|
|
2022
Q4 | $21.6M | Buy |
181,015
+574
| +0.3% | +$67.2K | 0.01% | 543 |
|
|
2022
Q3 | $19.2M | Sell |
180,441
-35,094
| -16% | -$3.56M | 0.01% | 557 |
|
|
2022
Q2 | $21M | Sell |
215,535
-1,564
| -0.7% | -$144K | 0.01% | 554 |
|
|
2022
Q1 | $20.4M | Buy |
217,099
+5,960
| +3% | +$505K | 0.01% | 577 |
|
|
2021
Q4 | $18M | Buy |
211,139
+29,646
| +16% | +$2.73M | ﹤0.01% | 616 |
|
|
2021
Q3 | $17.4M | Buy |
181,493
+38,165
| +27% | +$3.6M | 0.01% | 623 |
|
|
2021
Q2 | $13.9M | Sell |
143,328
-419
| -0.3% | -$40.2K | ﹤0.01% | 646 |
|
|
2021
Q1 | $14M | Sell |
143,747
-3,373
| -2% | -$354K | ﹤0.01% | 638 |
|
|
2020
Q4 | $14.1M | Buy |
147,120
+33,785
| +30% | +$3.26M | ﹤0.01% | 618 |
|
|
2020
Q3 | $10.9M | Sell |
113,335
-2,742
| -2% | -$317K | ﹤0.01% | 625 |
|
|
2020
Q2 | $14.2M | Sell |
116,077
-13,205
| -10% | -$1.46M | 0.01% | 582 |
|
|
2020
Q1 | $11.2M | Sell |
129,282
-2,944
| -2% | -$288K | 0.01% | 577 |
|
|
2019
Q4 | $14.2M | Buy |
132,226
+41
| +0% | +$4.29K | 0.01% | 567 |
|
|
2019
Q3 | $11.9M | Sell |
132,185
-495
| -0.4% | -$46.2K | ﹤0.01% | 590 |
|
|
2019
Q2 | $11.2M | Buy |
132,680
+11,096
| +9% | +$911K | ﹤0.01% | 610 |
|
|
2019
Q1 | $10.7M | Buy |
121,584
+19,926
| +20% | +$1.67M | ﹤0.01% | 605 |
|
|
2018
Q4 | $7.26M | Buy |
101,658
+11,239
| +12% | +$1.08M | ﹤0.01% | 636 |
|
|
2018
Q3 | $11.1M | Sell |
90,419
-4,428
| -5% | -$502K | ﹤0.01% | 609 |
|
|
2018
Q2 | $9.32M | Sell |
94,847
-25,657
| -21% | -$2.3M | ﹤0.01% | 634 |
|
|
2018
Q1 | $9.99M | Buy |
120,504
+11,869
| +11% | +$1M | ﹤0.01% | 612 |
|
|
2017
Q4 | $8.43M | Buy |
108,635
+1,437
| +1% | +$98K | ﹤0.01% | 636 |
|
|
2017
Q3 | $6.57M | Buy |
107,198
+652
| +0.6% | +$34.4K | ﹤0.01% | 645 |
|
|
2017
Q2 | $4.9M | Sell |
106,546
-17,463
| -14% | -$847K | ﹤0.01% | 674 |
|
|
2017
Q1 | $5.37M | Sell |
124,009
-189
| -0.2% | -$8.1K | ﹤0.01% | 647 |
|
|
2016
Q4 | $4.81M | Sell |
124,198
-309
| -0.2% | -$14K | ﹤0.01% | 671 |
|
|
2016
Q3 | $6.3M | Buy |
124,507
+2,104
| +2% | +$105K | ﹤0.01% | 627 |
|
|
2016
Q2 | $5.56M | Sell |
122,403
-4,108
| -3% | -$189K | ﹤0.01% | 640 |
|
|
2016
Q1 | $5M | Buy |
+126,511
| New | +$5.02M | ﹤0.01% | 642 |
|
Other funds holding NBIX
Massachusetts Financial Services's NBIX Position: Q2 2026 in Review
Massachusetts Financial Services increased its Neurocrine Biosciences (NBIX) stake by 0.45% in Q2 2026, buying an estimated $68.4K and bringing the position to 102,414 shares worth $17.3M. The position accounts for 0.01% of the portfolio, ranked #693.
Massachusetts Financial Services first reported a position in NBIX in Q1 2016 and has held it in 42 quarters since. The position peaked at $23.2M in Q4 2023. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Massachusetts Financial Services held 102,414 shares of Neurocrine Biosciences worth $17.3M as of Q2 2026.
- Massachusetts Financial Services bought 461 Neurocrine Biosciences shares in Q2 2026, an estimated $68.4K.
- Neurocrine Biosciences made up 0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #693 holding.
- Massachusetts Financial Services first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 42 quarters since.
- Massachusetts Financial Services's Neurocrine Biosciences position peaked at $23.2M in Q4 2023.
- 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.